Strong Synergy With APR-246 and DNA-damaging Drugs in Primary Cancer Cells From Patients With TP53 Mutant High-Grade Serous Ovarian Cancer

Journal of Ovarian Research - United Kingdom
doi 10.1186/s13048-016-0239-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Identification of Novel Somatic TP53 Mutations in Patients With High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

VISTA Expression Is Associated With a Favorable Prognosis in Patients With High-Grade Serous Ovarian Cancer

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Predictors of Long-Term Survival Among High-Grade Serous Ovarian Cancer Patients

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

Characterisation of Homologous Recombination Deficiency in Paired Primary and Recurrent High-Grade Serous Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Identification of Candidate Genes Associated With Tubal Origin of High‑grade Serous Ovarian Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Thrombocytosis and Hyperfibrinogenemia Are Predictive Factors of Clinical Outcomes in High-Grade Serous Ovarian Cancer Patients

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy